Metraipolis › archive › dc_62316c0bd7aa

Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma — Europe PMC PMID:41668195

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41668195
DOI
10.1186/s12962-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-05T23:24:27.374Z
SHA-256 of the archived text
6ff6a863c694f6b39025dd10ba4c3bb1f5254e025716f0d50647435ea1cc7da3
Stable URL of this page
https://metraipolis.com/documento/dc_62316c0bd7aa

How to cite

Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma — Europe PMC PMID:41668195 — Europe PMC (en), https://europepmc.org/article/MED/41668195 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_62316c0bd7aa (Metraipolis archive dc_62316c0bd7aa, sha256 6ff6a863c694f6b39025dd10ba4c3bb1f5254e025716f0d50647435ea1cc7da3)
BibTeX
@misc{dc62316c0bd7aa,
  title = {Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma — Europe PMC PMID:41668195},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41668195},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_62316c0bd7aa; sha256 6ff6a863c694f6b39025dd10ba4c3bb1f5254e025716f0d50647435ea1cc7da3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41668195. Agents can read the archived copy with the MCP tool read_document.